+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Global Solid Tumor Cancer Treatment Market Size, Market Share, Application Analysis, Regional Outlook, Growth Trends, Key Players, Competitive Strategies and Forecasts, 2019-2027

  • ID: 4828522
  • Report
  • Region: Global
  • Acute Market Reports
1 of 3

FEATURED COMPANIES

  • Amgen, Inc.
  • AstraZeneca, Plc.
  • B. Braun Melsungen AG
  • Eli Lilly & Company
  • F.Hoffman La-Roche Ltd.
  • Merck & Co., Inc.
  • MORE
The global solid tumor cancer treatment market was valued at US$ 121.3 Bn in 2018 and is expected to reach US$ 424.6 Bn by 2027, expanding at a CAGR of 15.0% from 2019 to 2027.

Market Insights

As per the research findings of the International Agency for Research (IARC) on Cancer in association with World Health Organization (WHO) in 2018, approximately 18.1 million new cases of cases were reported. They also claim that 1 in 6 women and 1 in 5 men are likely to develop cancer during their lifetime.

Breast cancer is dominating the indication segment for solid tumor cancer treatment market. The major factors hold responsible for its rising prevalence in the female population worldwide is hormonal imbalance during the menstrual cycle, unhealthy lifestyle and low or no breastfeeding during a lifetime. A significant spurt is expected to be seen in the prevalence rate of lung cancer throughout the globe on account of a significant rise in the number of smokers and rising air pollution at an alarming rate.

Chemotherapy is currently the largest market in the therapy segment for solid tumor cancer treatment. Availability of its generic version at affordable cost increases its popularity in treating cancer. It is used alone or in combination for treating tumors in different parts of the human body. Biological molecules such as immunotherapy and targeted therapy are gaining prominence in cancer treatment on account of its excellent pharmacodynamic features ensuring minimal side effects and maximum therapeutic efficacy. Favorable reimbursement scenario further increases its demand for cancer treatment.

North America presently holds a 33.6% market share in the regional segment for solid tumor cancer treatment market. According to the research citing brought forward by Center for Disease Control and Prevention, in a span of 10 years form 2010-2020, in the United States approximately 1 million cases will be reported in men population and 900,000 in female population annually. Europe accounts for 30.2% market share on account of a supportive regulatory environment provided by the European Medical Agency (EMA) for the development and sale of medicines used in the treatment of solid tumor cancer. The Asia Pacific with a share of 19.5% is set to register significant growth soon owing to the rising public health awareness regarding cancer and its treatment and developing healthcare infrastructure.

Pharmaceutical companies spearheading the solid tumor cancer treatment market are AstraZeneca, Plc., Amgen, Inc., B. Braun Melsungen AG, Bristol Myers Squibb & Company, Eli Lilly & Company, F.Hoffman La-Roche Ltd., Merck & Co., Inc., Novartis AG, Pfizer, Inc., and Olympus Medical Systems.

Key Market Movements
  • Significant rise in the diagnosis of new cases of cancer worldwide
  • The recent approval of biologics exhibiting excellent pharmacodynamic properties with minimal side effects
  • Affordable reimbursement scenario for medicines employed for the treatment of solid tumor cancer
Note: Product cover images may vary from those shown
2 of 3

FEATURED COMPANIES

  • Amgen, Inc.
  • AstraZeneca, Plc.
  • B. Braun Melsungen AG
  • Eli Lilly & Company
  • F.Hoffman La-Roche Ltd.
  • Merck & Co., Inc.
  • MORE
Chapter 1. Preface
1.1. Report Scope and Description
1.1.1. Purpose of the Report
1.1.2. Target Audience
1.1.3. USP and Key Offerings
1.2. Research Scope
1.3. Research Methodology
1.3.1. Phase I-Secondary Research
1.3.2. Phase II-Primary Research
1.3.3. Approach Adopted
1.3.4. Top-down Approach
1.3.5. Bottom-up Approach
1.3.6. Phase III-Expert Panel Review
1.3.7. Assumptions
1.4. Market Segmentation

Chapter 2. Executive Summary
2.1. Global Solid Tumor Cancer Treatment Market Portraiture
2.2. Global Solid Tumor Cancer Treatment Market, by Indication, 2018 (US$ Bn)
2.3. Global Solid Tumor Cancer Treatment Market, by Therapy, 2018 (US$ Bn)
2.4. Global Solid Tumor Cancer Treatment Market, by Geography, 2018 (US$ Bn)

Chapter 3. Solid Tumor Cancer Treatment Market: Dynamics and Future Outlook
3.1. Market Overview
3.2. Drivers
3.3. Challenges
3.4. Opportunities
3.5. Attractive Investment Proposition, by Geography, 2018
3.6. Competitive Analysis: Global Solid Tumor Cancer Treatment Market, by Key Players, 2018

Chapter 4. Global Solid Tumor Cancer Treatment Market, by Indication
4.1. Overview
4.2. Breast Cancer
4.3. Cervical Cancer
4.4. Colorectal Cancer
4.5. Lung Cancer
4.6. Prostate Cancer
4.7. Others (Brain Tumor, Pancreatic Cancer etc.)

Chapter 5. Global Solid Tumor Cancer Treatment Market, by Therapy
5.1. Chemotherapy
5.2. Targeted Therapy
5.3. Immunotherapy
5.4. Hormone Therapy
5.5. Surgical Procedures

Chapter 6. Global Solid Tumor Cancer Treatment Market, by Geography
6.1. Overview
6.2. North America Solid Tumor Cancer Treatment Market Analysis, 2017– 2027
6.2.1. North America Solid Tumor Cancer Treatment Market, by Indication, 2017 – 2027 (US$ Bn)
6.2.2. North America Solid Tumor Cancer Treatment Market, by Therapy, 2017 – 2027 (US$ Bn)
6.2.3. North America Solid Tumor Cancer Treatment Market, by Country, 2017 – 2027 (US$ Bn)
6.2.3.1. U.S.
6.2.3.2. Canada
6.3. Europe Solid Tumor Cancer Treatment Market Analysis, 2017 – 2027
6.3.1. Europe Solid Tumor Cancer Treatment Market, by Indication, 2017– 2027 (US$ Bn)
6.3.2. Europe Solid Tumor Cancer Treatment Market, by Therapy, 2017 – 2027 (US$ Bn)
6.3.3. Europe Solid Tumor Cancer Treatment Market, by Country/Region, 2017 – 2027 (US$ Bn)
6.3.3.1. U.K.
6.3.3.2. Germany
6.3.3.3. Rest of Europe
6.4. Asia Pacific Solid Tumor Cancer Treatment Market Analysis, 2017 – 2027
6.4.1. Asia Pacific Solid Tumor Cancer Treatment Market, by Indication, 2017 – 2027 (US$ Bn)
6.4.2. Asia Pacific Solid Tumor Cancer Treatment Market, by Therapy, 2017– 2027 (US$ Bn)
6.4.3. Asia Pacific Solid Tumor Cancer Treatment Market, by Country/Region, 2017 – 2027 (US$ Bn)
6.4.3.1. China
6.4.3.2. Japan
6.4.3.3. Rest of Asia Pacific
6.5. Latin America Solid Tumor Cancer Treatment Market Analysis, 2017 – 2027
6.5.1. Latin America Solid Tumor Cancer Treatment Market, by Indication, 2017 – 2027 (US$ Bn)
6.5.2. Latin America Solid Tumor Cancer Treatment Market, by Therapy, 2017 – 2027 (US$ Bn)
6.5.3. Latin America Solid Tumor Cancer Treatment Market, by Country/Region, 2017 – 2027 (US$ Bn)
6.5.3.1. Brazil
6.5.3.2. Mexico
6.5.3.3. Rest of Latin America
6.6. Middle East and Africa Solid Tumor Cancer Treatment Market Analysis, 2017 – 2027
6.6.1. MEA Solid Tumor Cancer Treatment Market, by Indication, 2017 – 2027 (US$ Bn)
6.6.2. MEA Solid Tumor Cancer Treatment Market, by Therapy, 2017 – 2027 (US$ Bn)
6.6.3. MEA Solid Tumor Cancer Treatment Market, by Country/Region, 2017 – 2027 (US$ Bn)
6.6.3.1. GCC
6.6.3.2. Rest of MEA

Chapter 7. Company Profiles
7.1. AstraZeneca, Plc.
7.1.1. Business Description
7.1.2. Financial Information (Subject to data availability)
7.1.3. Product Portfolio
7.1.4. News Coverage
7.2. Amgen, Inc.
7.3. B. Braun Melsungen AG
7.4. Bristol Myers Squibb & Company
7.5. Eli Lilly & Company
7.6. F.Hoffman La-Roche Ltd.
7.7. Merck & Co., Inc.
7.8. Novartis
7.9. Pfizer, Inc.
7.10. Olympus Medical Systems

List of Figures
Figure 1 Solid Tumor Cancer Treatment Market: Research Methodology
Figure 2 Solid Tumor Cancer Treatment: Market Segmentation
Figure 3 Global Solid Tumor Cancer Treatment Market, by Indication, 2018 (US$ Bn)
Figure 4 Global Solid Tumor Cancer Treatment Market, by Therapy, 2018 (US$ Bn)
Figure 5 Global Solid Tumor Cancer Treatment Market, by Geography, 2018 (US$ Bn)
Figure 6 Attractive Investment Proposition: by Geography, 2018
Figure 7 Competitive Analysis: Global Solid Tumor Cancer Treatment Market, by Key Players, 2018
Figure 8 Global Breast Solid Tumor Cancer Treatment Market, 2017 – 2027 (US$ Bn)
Figure 9 Global Cervical Solid Tumor Cancer Treatment Market, 2017– 2027 (US$ Bn)
Figure 10 Global Colorectal Solid Tumor Cancer Treatment Market, 2017 – 2027 (US$ Bn)
Figure 11 Global Lung Solid Tumor Cancer Treatment Market, 2017 – 2027 (US$ Bn)
Figure 12 Global Prostate Solid Tumor Cancer Treatment Market, 2017 – 2027 (US$ Bn)
Figure 13 Global Other Solid Tumor Cancer Treatment Market, 2017 – 2027 (US$ Bn)
Figure 14 Global Chemotherapy Market for Solid Tumor Cancer Treatment, 2017 – 2027 (US$ Bn)
Figure 15 Global Targeted Therapy Market for Solid Tumor Cancer Treatment, 2017 – 2027 (US$ Bn)
Figure 16 Global Immunotherapy Market for Solid Tumor Cancer Treatment, 2017 – 2027 (US$ Bn)
Figure 17 Global Hormone Therapy Market for Solid Tumor Cancer Treatment, 2017 – 2027 (US$ Bn)
Figure 18 Global Surgical Procedures Market for Solid Tumor Cancer Treatment, 2017 – 2027 (US$ Bn)
Figure 19 U.S. Solid Tumor Cancer Treatment Market, 2017 – 2027 (US$ Bn)
Figure 20 Canada Solid Tumor Cancer Treatment Market, 2017 – 2027 (US$ Bn)
Figure 21 U.K. Solid Tumor Cancer Treatment Market, 2017 – 2027 (US$ Bn)
Figure 22 Germany Solid Tumor Cancer Treatment Market, 2017– 2027 (US$ Bn)
Figure 23 Rest of Europe Solid Tumor Cancer Treatment Market, 2017 – 2027 (US$ Bn)
Figure 24 China Solid Tumor Cancer Treatment Market, 2017 – 2027 (US$ Bn)
Figure 25 Japan Solid Tumor Cancer Treatment Market, 2017 – 2027 (US$ Bn)
Figure 26 Rest of Asia Pacific Solid Tumor Cancer Treatment Market, 2017 – 2027 (US$ Bn)
Figure 27 Brazil Solid Tumor Cancer Treatment Market, 2017 – 2027 (US$ Bn)
Figure 28 Mexico Solid Tumor Cancer Treatment Market, 2017 – 2027 (US$ Bn)
Figure 29 Rest of Latin America Solid Tumor Cancer Treatment Market, 2017 – 2027 (US$ Bn)
Figure 30 GCC Solid Tumor Cancer Treatment Market, 2017 – 2027 (US$ Bn)
Figure 31 Rest of MEA Solid Tumor Cancer Treatment Market, 2017 – 2027 (US$ Bn)

List of Tables
Table 1 Global Solid Tumor Cancer Treatment Market Portraiture
Table 2 Global Solid Tumor Cancer Treatment Market, by Indication, 2017 – 2027 (US$ Bn)
Table 3 Global Solid Tumor Cancer Treatment Market , by Therapy, 2017 – 2027 (US$ Bn)
Table 4 Global Solid Tumor Cancer Treatment Market, by Geography, 2017 – 2027(US$ Bn)
Table 5 North America Solid Tumor Cancer Treatment Market, by Indication, 2017 – 2027 (US$ Bn)
Table 6 North America Solid Tumor Cancer Treatment Market, by Therapy, 2017 – 2027 (US$ Bn)
Table 7 North America Solid Tumor Cancer Treatment Market, by Country, 2017 – 2027 (US$ Bn)
Table 8 Europe Solid Tumor Cancer Treatment Market, by Indication, 2017 – 2027 (US$ Bn)
Table 9 Europe Solid Tumor Cancer Treatment Market, by Therapy, 2017 – 2027(US$ Bn)
Table 10 Europe Solid Tumor Cancer Treatment Market, by Country/Region, 2017 – 2027 (US$ Bn)
Table 11 Asia Pacific Solid Tumor Cancer Treatment Market, by Indication, 2017 – 2027 (US$ Bn)
Table 12 Asia Pacific Solid Tumor Cancer Treatment Market, by Therapy, 2017 – 2027 (US$ Bn)
Table 13 Asia Pacific Solid Tumor Cancer Treatment Market, by Country/Region, 2017– 2027 (US$ Bn)
Table 14 Latin America Solid Tumor Cancer Treatment Market, by Indication, 2017 – 2027 (US$ Bn)
Table 15 Latin America Solid Tumor Cancer Treatment Market, by Therapy, 2017 – 2027 (US$ Bn)
Table 16 Latin America Solid Tumor Cancer Treatment Market, by Country/Region, 2017 – 2027 (US$ Bn)
Table 17 Middle East and Africa Solid Tumor Cancer Treatment Market, by Indication, 2017 – 2027 (US$ Bn)
Table 18 Middle East and Africa Solid Tumor Cancer Treatment Market, by Therapy, 2017 – 2027 (US$ Bn)
Table 19 Middle East and Africa Solid Tumor Cancer Treatment Market, by Country/Region, 2017 – 2027 (US$ Bn)
Table 20 AstraZeneca, Plc.: Company Snapshot (Business Description; Financial Information; Product Portfolio; Key Developments)
Table 21 Amgen, Inc.: Company Snapshot (Business Description; Financial Information; Product Portfolio; Key Developments)
Table 22 B. Braun Melsungen AG: Company Snapshot (Business Description; Financial Information; Product Portfolio; Key Developments)
Table 23 Bristol Myers Squibb & Company: Company Snapshot (Business Description; Financial Information; Product Portfolio; Key Developments)
Table 24 Eli Lilly & Company: Company Snapshot (Business Description; Financial Information; Product Portfolio; Key Developments)
Table 25 F.Hoffman La-Roche Ltd.: Company Snapshot (Business Description; Financial Information; Product Portfolio; Key Developments)
Table 26 Merck & Co., Inc.: Company Snapshot (Business Description; Financial Information; Product Portfolio; Key Developments)
Table 27 Novartis AG: Company Snapshot (Business Description; Financial Information; Product Portfolio; Key Developments)
Table 28 Pfizer, Inc.: Company Snapshot (Business Description; Financial Information; Product Portfolio; Key Developments)
Table 29 Olympus Medical Systems: Company Snapshot (Business Description; Financial Information; Product Portfolio; Key Developments)
Note: Product cover images may vary from those shown
3 of 3

Loading
LOADING...

4 of 3
  • AstraZeneca, Plc.
  • Amgen, Inc.
  • B. Braun Melsungen AG
  • Bristol Myers Squibb & Company
  • Eli Lilly & Company
  • F.Hoffman La-Roche Ltd.
  • Merck & Co., Inc.
  • Novartis
  • Pfizer, Inc.
  • Olympus Medical Systems
Note: Product cover images may vary from those shown
Adroll
adroll